Jul 2026
Discovery of BBI-355, a Potent, Selective, and Orally Available Checkpoint Kinase 1 Inhibitor for the Treatment of Extrachromosomal DNA Oncogene-Amplified Cancers.
BBI-355, a potent, selective, and orally available CHK1 inhibitor, demonstrates strong antitumor activity when dosed orally in mouse xenograft models, achieving regressions both as a single agent and in combination with targeted therapies.
S. Meyer, Sudhir Chowdhry, Rachelle Elsdon et al.
· Journal of Medicinal Chemist... · 0 citations